Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P . (22nd April 2022)

• Record Type: Journal Article
• Authors: Kuo, Tsun-Yung; Lien, Chia En; Lin, Yi-Jiun; Lin, Meei-Yun; Wu, Chung-Chin; Tang, Wei-Hsuan; Campbell, John D; Traquina, Paula; Chuang, Ya-Shan; Liu, Luke Tzu-Chi; Cheng, Jinyi; Chen, Charles
• Is Part Of: Journal of infectious diseases. Volume 226:Number 9(2022)
• Page Start: 1562
• Page End: 1567
• Publication Date: 2022-04-22
• Subjects: SARS-CoV-2 vaccine -- COVID-19 vaccine -- subunit vaccine -- MVC-COV1901 -- hamster challenge study -- variant of concern; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac153
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern negatively impact the effectiveness of vaccines. In this study, we challenge hamsters with the delta variant after 2- or 3-dose inoculations with SARS-CoV-2 vaccines constructed from stabilized prefusion spike proteins (S-2P) of Wuhan (W) and beta (B) variants. Compared to 3 doses of W S-2P, 2 doses of W S-2P followed by a third dose of B S-2P induced the highest neutralizing antibody titer against live SARS-CoV-2 virus and enhanced neutralization of omicron variant pseudovirus. Reduced lung live virus titer and pathology suggested that all vaccination regimens protect hamsters from SARS-CoV-2 delta variant challenge. Abstract : Two doses of adjuvanted recombinant Wuhan strain SARS-CoV-2 spike protein (S-2P) vaccine followed by a booster dose of the beta variant S-2P provided broad-spectrum neutralization against variants of concern and protected hamsters from delta variant challenge.